Rapid Molecular Diagnostic Platform Sends Precise COVID-19 RNA Results to Smartphone in Minutes
By LabMedica International staff writers Posted on 05 Mar 2021 |
Image: Rapid Molecular Diagnostic Platform Sends Precise COVID-19 RNA Results to Smartphone in Minutes (Photo courtesy of Purdue University/Chris Adam)
An all new technology can detect COVID-19 RNA in saliva through newly developed electronic nanosensors, which significantly reduces error rates associated with chemical-based home tests.
IdentifySensors Biologics (Cleveland, OH, USA), a nanosensor technology firm which has developed the rapid diagnostic platform for detecting pathogens, including SARS-CoV-2, has now joined the SMART Film Consortium, led by the Birck Nanotechnology Center at Purdue University (West Lafayette, IN, USA) that seeks to develop the first foundry dedicated to low-cost non-silicon printed sensors.
Unlike other molecular tests for COVID-19, the rapid molecular diagnostic platform automatically transmits test results to consumer smartphones and to the proper health agencies in minutes. The platform technology can be easily modified to also detect influenza, Zika, dengue, HIV/AIDS, hepatitis C, Lyme disease, mumps, measles, chickenpox and methicillin-resistant staphylococcus Aureus (MRSA) and foodborne pathogens.
"By joining the SMART Film Consortium, IdentifySensors Biologics has positioned itself in a significantly strategic vantage point where it is able to tap into a wide array of printing and scalable manufacturing resources in the Birck Nanotechnology Center to greatly accelerate the development of their COVID-19 sensor," said Thomas Sors, assistant director of the Purdue Institute of Inflammation, Immunology and Infectious Disease.
Related Links:
IdentifySensors Biologics
Purdue Research Foundation
IdentifySensors Biologics (Cleveland, OH, USA), a nanosensor technology firm which has developed the rapid diagnostic platform for detecting pathogens, including SARS-CoV-2, has now joined the SMART Film Consortium, led by the Birck Nanotechnology Center at Purdue University (West Lafayette, IN, USA) that seeks to develop the first foundry dedicated to low-cost non-silicon printed sensors.
Unlike other molecular tests for COVID-19, the rapid molecular diagnostic platform automatically transmits test results to consumer smartphones and to the proper health agencies in minutes. The platform technology can be easily modified to also detect influenza, Zika, dengue, HIV/AIDS, hepatitis C, Lyme disease, mumps, measles, chickenpox and methicillin-resistant staphylococcus Aureus (MRSA) and foodborne pathogens.
"By joining the SMART Film Consortium, IdentifySensors Biologics has positioned itself in a significantly strategic vantage point where it is able to tap into a wide array of printing and scalable manufacturing resources in the Birck Nanotechnology Center to greatly accelerate the development of their COVID-19 sensor," said Thomas Sors, assistant director of the Purdue Institute of Inflammation, Immunology and Infectious Disease.
Related Links:
IdentifySensors Biologics
Purdue Research Foundation
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants